Lv, J.; Xing, C.; Chen, Y.; Bian, H.; Lv, N.; Wang, Z.; Liu, M.; Su, L.
The STING in Non-Alcoholic Fatty Liver Diseases: Potential Therapeutic Targets in Inflammation-Carcinogenesis Pathway. Pharmaceuticals 2022, 15, 1241.
https://doi.org/10.3390/ph15101241
AMA Style
Lv J, Xing C, Chen Y, Bian H, Lv N, Wang Z, Liu M, Su L.
The STING in Non-Alcoholic Fatty Liver Diseases: Potential Therapeutic Targets in Inflammation-Carcinogenesis Pathway. Pharmaceuticals. 2022; 15(10):1241.
https://doi.org/10.3390/ph15101241
Chicago/Turabian Style
Lv, Juan, Chunlei Xing, Yuhong Chen, Huihui Bian, Nanning Lv, Zhibin Wang, Mingming Liu, and Li Su.
2022. "The STING in Non-Alcoholic Fatty Liver Diseases: Potential Therapeutic Targets in Inflammation-Carcinogenesis Pathway" Pharmaceuticals 15, no. 10: 1241.
https://doi.org/10.3390/ph15101241
APA Style
Lv, J., Xing, C., Chen, Y., Bian, H., Lv, N., Wang, Z., Liu, M., & Su, L.
(2022). The STING in Non-Alcoholic Fatty Liver Diseases: Potential Therapeutic Targets in Inflammation-Carcinogenesis Pathway. Pharmaceuticals, 15(10), 1241.
https://doi.org/10.3390/ph15101241